Dresden

• An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended recruitment
  2023-507906-15-00 5 2019-01-30 Relapsing multiple sclerosis (RMS)
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma … Ended recruitment
  2022-502937-24-00 5 2019-01-02 Atopic Dermatitis
• Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended recruitment
  2023-506921-12-00 5 2018-12-27 ER+/HER2- Breast Cancer
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat … Ended recruitment
  2024-513912-89-00 10 2018-12-13 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
• A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio … Ended recruitment
  2024-513464-26-00 5 2018-10-18 Multiple Myeloma
• DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended recruitment
  2024-514945-12-00 10 2018-09-03 locally advanced resectable adenocarcinoma of the oesophagogastric jun
• Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel … Ended recruitment
  2024-515783-31-00 5 2018-08-24 Newly Diagnosed Multiple Myeloma
• A Study of Efficacy, Safety, and Pharmacokinetics of Guselkumab in the Treatment of Chronic Plaque Psoriasis in Pediatric Participants Ended recruitment
  2023-503378-19-00 5 2018-08-23 Chronic Plaque Psoriasis
• Extended Access of Momelotinib for Subjects with Myelofibrosis Ended recruitment
  2023-508018-41-00 4 2018-07-27 Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended recruitment
  2023-509856-32-00 5 2018-07-15 acute lymphoblastic leukemia in children and adolescents
• A trial funded by the German Federal Ministry for Education and Research (BMBF) to evaluate the effects of closed-loop automatic control of … Ended recruitment
  2024-511335-10-01 5 2018-07-01 Preterm infants with a gestational age (GA) at birth of 23+0/7 – 27+6/
• A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis Ended recruitment
  2023-506429-13-00 5 2018-05-02 Progressive multiple sclerosis (PMS)
• Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended recruitment
  2023-504820-24-00 5 2018-03-21 Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended recruitment
  2024-513070-21-00 4 2018-02-15 Relapsed Acute Lymphoblastic Leukemia (ALL)
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and … Ended recruitment
  2023-505509-18-00 5 2017-07-12 mature aggressive B-cell lymphoma and leukemia in children and adolesc
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended recruitment
  2023-509671-17-00 5 2017-07-12 Breast Cancer
• Study with investigational drug PF-06463922 and comparator crizotinib in patients with a specific type of advanced lung cancer Ended recruitment
  2023-509169-19-00 5 2017-07-11 Advanced ALK positive non-small cell lung cancer
• A study to decide what is the highest dose of CC-220 to take alone and with other standard of care treatments to assess the side effects, ef … Ended recruitment
  2024-510799-19-00 9 2016-08-09 Multiple Myeloma
• Study of Tumor Alterations Responsive to Targeting Receptor Kinases-2 Ended recruitment
  2023-505034-10-00 4 2016-08-01 Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS
• Neoadjuvant L19IL2/L19TNF- Pivotal study Ended recruitment
  2024-515749-40-00 5 2016-02-25 Malignant melanoma of the skin in patients with locally advanced and f
• EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) wit … Ended recruitment
  2024-513509-30-00 5 2016-01-11 Progressive or recurrent germ cell tumor (measurable or non-measurable
• Study to Evaluate Imetelstat (GRN163L) in Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Ended recruitment
  2024-511348-25-00 10 2015-12-11 Myelodysplastic syndromes (MDS)
• Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). Ended recruitment
  2023-509425-53-00 5 2015-11-09 Atopic Dermatitis

Showing 697–720 of 943 trials